VSV-IFNbeta-TYRP1

VSV-IFNbeta-TYRP1 is a recombinant, replicating oncolytic virus based on the Vesicular Stomatitis Virus (VSV) platform. It is engineered to carry and express two therapeutic transgenes: the human interferon-beta (IFN-β) gene and the tyrosinase-related protein 1 (TYRP1) gene. The virus selectively replicates in and lyses tumor cells, which often lack the innate antiviral defenses present in healthy cells. The expression of IFN-β serves a dual purpose: it enhances safety by inducing an antiviral state in surrounding normal cells to prevent non-specific viral replication, and it stimulates the recruitment and activation of cytotoxic T lymphocytes, dendritic cells, and natural killer cells. The inclusion of TYRP1, a melanoma-associated antigen, is designed to prime the immune system to recognize and attack TYRP1-expressing melanoma cells specifically, potentially leading to systemic anti-tumor immunity and epitope spreading. Primarily developed by the Mayo Clinic in collaboration with the National Cancer Institute, it has been investigated in Phase 1 clinical trials for advanced cutaneous and uveal melanomas.

Other names

recombinant vesicular stomatitis virus-expressing interferon-beta and tyrosinase related protein 1VSV-IFN-beta/TYRP1VSV-IFNbetaTYRP1VSV-IFNbetaTYRP-1VSV-IFNbetaTYRP 1